New and Updated Clinical Ebola Vaccine Trials
-
REVIVE (Response to the Ebola Virus Vaccine)
Aug 15, 2023 | 18:00 pmCondition: Ebola Virus DiseaseIntervention: Biological: rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)Sponsors: Tulane University; Kenema Government Hospital; Merck Sharp & Dohme LLCNot yet recruiting
-
Prophylaxis Vaccine Antibodies Ebola
Mar 30, 2021 | 18:00 pmCondition: Ebola Virus DiseaseInterventions: Drug: ansuvimab; Biological: ErveboSponsor: ANRS, Emerging Infectious DiseasesNot yet recruiting
-
Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC
Nov 5, 2019 | 18:00 pmCondition: Ebola Virus DiseaseIntervention: Biological: Ad26.ZEBOV, MVA-BN-Filo vaccineSponsors: London School of Hygiene and Tropical Medicine; Epicentre; Ministère de la Santé de la RDC; Médecins Sans Frontières, France; Coalition for Epidemic Preparedness Innovations; Janssen Vaccines & Prevention B.V.; Public Health EnglandUnknown status
-
Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Aug 1, 2019 | 18:00 pmCondition: Ebola VirusIntervention: Biological: cAd3-EBO S vaccineSponsors: National Institute of Allergy and Infectious Diseases (NIAID); US Military HIV Research ProgramCompleted
-
Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
Oct 25, 2018 | 18:00 pmCondition: Ebola VirusInterventions: Drug: ZMapp; Drug: Remdesivir; Drug: MAb114; Drug: REGN-EB3Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
May 4, 2017 | 18:00 pmCondition: Ebola Virus DiseaseIntervention: Biological: Previously exposed to Ebola vaccineSponsors: University of Oxford; University of GlasgowCompleted
-
PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Apr 4, 2017 | 18:00 pmCondition: Ebola Virus DiseaseIntervention: Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
Jan 26, 2017 | 18:00 pmCondition: EbolaInterventions: Biological: V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine; Other: SalineSponsors: Cecile Tremblay; Merck Sharp & Dohme LLC; International Development Research Centre, Canada; Dalhousie University; Université de Montréal; Coalition for Epidemic Preparedness InnovationsActive, not recruiting
-
Partnership for Research on Ebola VACcinations
Aug 23, 2016 | 18:00 pmCondition: Ebola Virus DiseaseInterventions: Biological: Ad26.ZEBOV; Biological: MVA-BN-Filo; Biological: rVSVΔG-ZEBOV-GP; Biological: Placebo; Biological: rVSV boostSponsors: National Institute of Allergy and Infectious Diseases (NIAID); Partnership for Research on Ebola Virus in Liberia (PREVAIL); Institut National de la Santé Et de la Recherche Médicale, France; London School of Hygiene and Tropical Medicine; European and Developing Countries Clinical Trials Partnership (EDCTP)Active, not recruiting
-
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Jun 29, 2016 | 18:00 pmCondition: EbolaInterventions: Drug: GS-5734; Other: Placebo ComparatorSponsors: National Institute of Allergy and Infectious Diseases (NIAID); Gilead SciencesCompleted
-
Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults
Mar 24, 2016 | 17:00 pmCondition: Ebola Virus DiseaseInterventions: Biological: Ebola Vaccine - low dose; Biological: Ebola Vaccine - mid dose; Biological: Ebola Vaccine - high dose; Biological: PlaceboSponsors: Auro Vaccines LLC; Accelovance; United States Department of DefenseCompleted
-
A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization
Aug 27, 2015 | 18:00 pmCondition: Ebola Virus DiseaseInterventions: Biological: 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV); Biological: 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV); Biological: placeboSponsors: Jiangsu Province Centers for Disease Control and Prevention; Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology IncCompleted
-
Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
May 1, 2015 | 18:00 pmCondition: Ebola Virus DiseaseIntervention: Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
Mar 4, 2015 | 18:00 pmCondition: Hemorrhagic Fever, EbolaIntervention: Biological: rVSVΔG-ZEBOVSponsors: Centers for Disease Control and Prevention; University of Sierra Leone; Ministry of Health and Sanitation, Sierra Leone; Department of Health and Human Services; eHealth AfricaCompleted
-
Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda
Feb 3, 2015 | 18:00 pmCondition: Hemorrhagic Fever, EbolaInterventions: Biological: cAd3-EBOZ; Biological: cAd3-EBO; Biological: MVA-EbolaZSponsors: National Institute of Allergy and Infectious Diseases (NIAID); US Military HIV Research Program; The Emmes Company, LLCCompleted
-
Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Jan 26, 2015 | 18:00 pmCondition: Ebola VirusInterventions: Biological: VSVG-ZEBOV; Biological: ChAd3-EBO Z; Biological: PlaceboSponsor: National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
Jan 19, 2015 | 18:00 pmCondition: Hemorrhagic Fever, EbolaIntervention: Other: Convalescent PlasmaSponsors: Institute of Tropical Medicine, Belgium; National Blood Transfusion Centre (NBTC), Conakry, Guinea; Gamal Abdel Nasser University of Conakry; National Center for Training and Research of Maferinyah, Guinea; Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo; University of Oxford; University of Liverpool; London School of Hygiene and Tropical Medicine; Aix Marseille Université; UBIVE, Institut Pasteur, Paris, France; Institut National de la Santé Et de la Recherche Médicale, France; Etablissement Français du Sang; Belgian Red Cross; Institut Pasteur, Dakar, Sénégal; Médecins Sans Frontières, Belgium; World Health Organization; International Severe Acute Respiratory and Emerging Infection ConsortiumCompleted
-
A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.
Dec 25, 2014 | 18:00 pmCondition: Ebola Virus DiseaseInterventions: Biological: Low dose Ebola Zaire vaccine (Ad5-EBOV); Biological: High dose Ebola Zaire vaccine (Ad5-EBOV); Biological: placebo (one dose); Biological: placebo (two doses)Sponsors: Jiangsu Province Centers for Disease Control and Prevention; Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology IncCompleted
-
A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Sep 16, 2014 | 18:00 pmConditions: Ebola; Ebola ZaireInterventions: Biological: cAd3-EBO Z at 1 x 10^10 vp; Biological: cAd3-EBO Z at 2.5 x 10^10 vp; Biological: cAd3-EBO Z at 5 x 10^10 vp; Biological: 4.4x10^8 TCID50s MVA-BN® Filo; Biological: 2.2x10^8 TCID50s MVA-BN® Filo; Biological: 4.4 x 10^7 TCID50s MVA-BN® FiloSponsors: University of Oxford; Wellcome Trust; National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Evaluating an Ebola and a Marburg Vaccine in Uganda
Oct 19, 2009 | 18:00 pmConditions: Ebola Virus Disease; Marburg Virus DiseaseInterventions: Biological: Ebola vaccine; Biological: Marburg vaccine; Other: Placebo injectionSponsor: National Institute of Allergy and Infectious Diseases (NIAID)Completed